Literature DB >> 27600518

Strength Testing in Motor Neuron Diseases.

Jeremy M Shefner1.   

Abstract

Loss of muscle strength is a cardinal feature of all motor neuron diseases. Functional loss over time, including respiratory dysfunction, inability to ambulate, loss of ability to perform activities of daily living, and others are due, in large part, to decline in strength. Thus, the accurate measurement of limb muscle strength is essential in therapeutic trials to best understand the impact of therapy on vital function. While qualitative strength measurements show declines over time, the lack of reproducibility and linearity of measurement make qualitative techniques inadequate. A variety of quantitative measures have been developed; all have both positive attributes and limitations. However, with careful training and reliability testing, quantitative measures have proven to be reliable and sensitive indicators of both disease progression and the impact of experimental therapy. Quantitative strength measurements have demonstrated potentially important therapeutic effects in both amyotrophic lateral sclerosis and spinobulbar muscular atrophy, and have been shown feasible in children with spinal muscular atrophy. The spectrum of both qualitative and quantitative strength measurements are reviewed and their utility examined in this review.

Entities:  

Keywords:  Hand held dynamometry; Manual muscle testing; Motor neuron disease; Spinal muscular atrophy; TQNE

Mesh:

Year:  2017        PMID: 27600518      PMCID: PMC5233619          DOI: 10.1007/s13311-016-0472-0

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  41 in total

1.  Relationship between two measures of upper extremity strength: manual muscle test compared to hand-held myometry.

Authors:  S Schwartz; M E Cohen; G J Herbison; A Shah
Journal:  Arch Phys Med Rehabil       Date:  1992-11       Impact factor: 3.966

2.  A comparison of three measures of disease progression in ALS.

Authors:  P L Andres; L M Skerry; B Thornell; L G Portney; L J Finison; T L Munsat
Journal:  J Neurol Sci       Date:  1996-08       Impact factor: 3.181

3.  Pilot trial of clenbuterol in spinal and bulbar muscular atrophy.

Authors:  Giorgia Querin; Carla D'Ascenzo; Enrico Peterle; Mario Ermani; Luca Bello; Paola Melacini; Lucia Morandi; Letizia Mazzini; Vincenzo Silani; Monika Raimondi; Jessica Mandrioli; Silvia Romito; Corrado Angelini; Elena Pegoraro; Gianni Sorarù
Journal:  Neurology       Date:  2013-05-03       Impact factor: 9.910

4.  The natural history of motoneuron loss in amyotrophic lateral sclerosis.

Authors:  T L Munsat; P L Andres; L Finison; T Conlon; L Thibodeau
Journal:  Neurology       Date:  1988-03       Impact factor: 9.910

5.  A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis.

Authors:  Jeremy M Shefner; Andrew A Wolff; Lisa Meng; Amy Bian; Jacqueline Lee; Donna Barragan; Jinsy A Andrews
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2016-03-16       Impact factor: 4.092

6.  A placebo-controlled trial of gabapentin in spinal muscular atrophy.

Authors:  R G Miller; D H Moore; V Dronsky; W Bradley; R Barohn; W Bryan; T W Prior; D F Gelinas; S Iannaccone; J Kissel; R Leshner; J Mendell; M Mendoza; B Russman; F Samaha; S Smith
Journal:  J Neurol Sci       Date:  2001-10-15       Impact factor: 3.181

7.  Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

Authors:  Paul H Gordon; Dan H Moore; Robert G Miller; Julaine M Florence; Joseph L Verheijde; Carolyn Doorish; Joan F Hilton; G Mark Spitalny; Robert B MacArthur; Hiroshi Mitsumoto; Hans E Neville; Kevin Boylan; Tahseen Mozaffar; Jerry M Belsh; John Ravits; Richard S Bedlack; Michael C Graves; Leo F McCluskey; Richard J Barohn; Rup Tandan
Journal:  Lancet Neurol       Date:  2007-11-05       Impact factor: 44.182

8.  A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis.

Authors:  M E Cudkowicz; J M Shefner; D A Schoenfeld; R H Brown; H Johnson; M Qureshi; M Jacobs; J D Rothstein; S H Appel; R M Pascuzzi; T D Heiman-Patterson; P D Donofrio; W S David; J A Russell; R Tandan; E P Pioro; K J Felice; J Rosenfeld; R N Mandler; G M Sachs; W G Bradley; E M Raynor; G D Baquis; J M Belsh; S Novella; J Goldstein; J Hulihan
Journal:  Neurology       Date:  2003-08-26       Impact factor: 9.910

9.  Change in muscle strength over time in spinal muscular atrophy types II and III. A long-term follow-up study.

Authors:  U Werlauff; J Vissing; B F Steffensen
Journal:  Neuromuscul Disord       Date:  2012-11-03       Impact factor: 4.296

10.  Somatropin treatment of spinal muscular atrophy: a placebo-controlled, double-blind crossover pilot study.

Authors:  J Kirschner; D Schorling; D Hauschke; C Rensing-Zimmermann; U Wein; U Grieben; G Schottmann; U Schara; K Konrad; W Müller-Felber; S Thiele; E Wilichowski; E Hobbiebrunken; G M Stettner; R Korinthenberg
Journal:  Neuromuscul Disord       Date:  2013-11-13       Impact factor: 4.296

View more
  6 in total

1.  An Appraisal of Novel Biomarkers for Evaluating and Monitoring Neurologic Diseases: Editorial Introduction.

Authors:  Jeremy M Shefner; Marwan N Sabbagh
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

2.  Lower-extremity Dynamometry as a Novel Outcome Measure in a Double-blind, Placebo-controlled, Feasibility Trial of Intravenous Immunoglobulin (IVIG) for HIV-associated Myelopathy.

Authors:  Jessica Robinson-Papp; Mary Catherine George; Alexandra Nmashie; Donald Weisz; David M Simpson
Journal:  Innov Clin Neurosci       Date:  2018-02-01

3.  Intraspinal Transplantation of the Adipose Tissue-Derived Regenerative Cells in Amyotrophic Lateral Sclerosis in Accordance with the Current Experts' Recommendations: Choosing Optimal Monitoring Tools.

Authors:  Magdalena Kuzma-Kozakiewicz; Andrzej Marchel; Anna Kaminska; Malgorzata Gawel; Jan Sznajder; Anna Figiel-Dabrowska; Arkadiusz Nowak; Edyta Maj; Natalia Ewa Krzesniak; Bartlomiej H Noszczyk; Krystyna Domanska-Janik; Anna Sarnowska
Journal:  Stem Cells Int       Date:  2018-08-12       Impact factor: 5.443

4.  The Measurement of Strength in Children: Is the Peak Value Truly Maximal?

Authors:  Hayao Ozaki; Takashi Abe; Scott J Dankel; Jeremy P Loenneke; Toshiharu Natsume; Pengyu Deng; Hisashi Naito
Journal:  Children (Basel)       Date:  2020-12-26

5.  Progressive arm muscle weakness in ALS follows the same sequence regardless of onset site: use of TOMS, a novel analytic method to track limb strength.

Authors:  Nimish J Thakore; Brian J Drawert; Brittany R Lapin; Erik P Pioro
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2021-02-23       Impact factor: 3.528

6.  Maximum isometric torque at individually-adjusted joint angles exceeds eccentric and concentric torque in lower extremity joint actions.

Authors:  Andreas Stotz; Ebrahem Maghames; Joel Mason; Andreas Groll; Astrid Zech
Journal:  BMC Sports Sci Med Rehabil       Date:  2022-01-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.